Year 2016 / Volume 108 / Number 2
Letter to the Editor
Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

104

DOI: 10.17235/reed.2015.3978/2015

Eugènia Santacana Juncosa, Ariadna Padullés Zamora, Helena Colom Codina, Lorena Rodríguez Alonso, Jordi Guardiola Capo, Jordi Bas Minguet, Núria Padullés Zamora,

Abstract
We read with great interest the paper by Pérez-Pitarch et al. entitled A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. We considered appropriate to highlight some aspects of the topic which were not addressed by the authors and according to our experience with therapeutic drug monitoring (TDM) of IFX in patients with inflammatory bowel disease (IBD). Although the causes of lack of response to anti-TNF drugs are multifactorial, the inter- and intra-individual pharmacokinetic (PK) variability plays an essential role. In that sense, two validated PPK models have been published for IFX in IBD patients. In our experience no correlation was found between individual model-predicted IFX concentrations (Cipred) and observed IFX concentrations (Cobs) when using the PPK model developed in UC in patients diagnosed of UC, whereas a good correlation was observed when using the Crohn disease (CD) PPK model with the same samples.
Share Button
New comment
Comments
No comments for this article
References
1 Pérez-Pitarch A, Ferriols-Lisart R, Alós-Almiñana M, Mínguez-Pérez M. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. Rev Esp Enferm Dig 2015;107:137-42.
2 Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011;33:987-95
3 Fasanmade AA, Adedokun OJ, Ford J et al. Population pharmacokinetic analysis of Infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28.
4 Fasanmade AA, Adedokun OJ, Blank M et al. Pharmacokinetic properties of Infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011;33:946-62.
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Citation tools
Santacana Juncosa E, Padullés Zamora A, Colom Codina H, Rodríguez Alonso L, Guardiola Capo J, Bas Minguet J, et all. Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients. 3978/2015


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 850 visits.
This article has been downloaded 57 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 19/08/2015

Accepted: 31/08/2015

Online First: 23/11/2015

Published: 01/02/2016

Article revision time: 3 days

Article Online First time: 96 days

Article editing time: 166 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology